Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConvaTec Group PLC

https://www.convatec.com/

Latest From ConvaTec Group PLC

Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Commercial Sales & Earnings

Finance Watch: Billions In And Billions Out In Venture Capital Fundraising

Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.

Financing StartUps and SMEs

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Consumables, Central Supplies
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
    • Rehabilitation Equipment and Devices
    • Surgical Equipment & Devices
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Hospitak, Inc.
    • Maersk Medical
    • Unomedical a/s
    • Woodbury Holdings
    • ConvaTec, Inc.
UsernamePublicRestriction

Register